Apellis Pharmaceuticals (APLS)
(Real Time Quote from BATS)
$35.17 USD
-0.83 (-2.31%)
Updated Aug 2, 2024 10:38 AM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APLS 35.17 -0.83(-2.31%)
Will APLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
Qiagen (QGEN) Tops Q2 Earnings and Revenue Estimates
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
Other News for APLS
Oppenheimer Remains a Buy on Apellis Pharmaceuticals (APLS)
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
Buy Rating on Apellis Pharmaceuticals: Market Potential and Strong Performance of Syfovre Despite Competition
Buy Rating Affirmed: Apellis Pharmaceuticals’ Syfovre Poised for Blockbuster Status Amid Competitive GA Market
Apellis price target lowered by $9 at H.C. Wainwright, here's why